Today, 360 Degree virtual tours is the newest tool for different industries to interact with their customers. Not only are they capturing a wider market margin but also they are able to keep up with their existing customers. And Lonza Group AG, world’s leading custom manufacturer of chemical and biological therapeutics find this interactive technology effective and futuristic that they even built a separate online website for customers to visit their worldwide locations: www.lonzavirtualtours.com
What can 360 Degree Virtual Tours do?
The Lonza Group partnered with creative agency, Enrich Media, to create an interactive video where viewers can see and experience Lonza’s development and production operations daily seamlessly. Their Lonza virtual tours are so intuitive that users can navigate their way through these plantations with ease – from Houston, TX to Cambridge, UK.
Once on their site, you pick which Lonza site you wish to visit virtually. Lonza’s 360 degree virtual tours include tours to custom manufacturing facilities, Early Target Analysis Services, Development, and Pilot Productions, Commercial Scale Manufacturing and Synthesis and more.
According to Dr. Karin Maag, Senior Director of Marketing, Lonza Custom Manufacturing, “Our new virtual tours provide a high level of transparency to our customers allowing them to fully experience and explore our facilities, globally, on their own schedule and from their own location. We value the importance of a strong global presence in today’s market, while understanding the limitations on travel for preliminary visitations.”
Who needs money to travel these days?
FOR FURTHER INFORMATION
Lonza Group Ltd
Tel +1 201 316 9413
Fax +1 201 696 3533
Lonza is one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cellbased research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza is not subject to the SGX-ST’s continuing listing requirements. Lonza is subject to the listing rules of the SIX Swiss Exchange, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realizations, and delisting. In 2011, the company had sales of CHF 2.69 billion. Further information can be found at www.lonza.com.